Logo image of ACET

ADICET BIO INC (ACET) Stock Fundamental Analysis

USA - NASDAQ:ACET - US0070021086 - Common Stock

0.6569 USD
+0.02 (+2.7%)
Last: 11/10/2025, 8:00:00 PM
0.6698 USD
+0.01 (+1.96%)
After Hours: 11/10/2025, 8:00:00 PM
Fundamental Rating

3

Overall ACET gets a fundamental rating of 3 out of 10. We evaluated ACET against 531 industry peers in the Biotechnology industry. While ACET has a great health rating, there are worries on its profitability. ACET does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ACET had negative earnings in the past year.
In the past year ACET has reported a negative cash flow from operations.
In the past 5 years ACET always reported negative net income.
In the past 5 years ACET always reported negative operating cash flow.
ACET Yearly Net Income VS EBIT VS OCF VS FCFACET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

ACET's Return On Assets of -61.23% is in line compared to the rest of the industry. ACET outperforms 42.00% of its industry peers.
ACET has a Return On Equity of -72.54%. This is comparable to the rest of the industry: ACET outperforms 55.56% of its industry peers.
Industry RankSector Rank
ROA -61.23%
ROE -72.54%
ROIC N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ACET Yearly ROA, ROE, ROICACET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACET so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACET Yearly Profit, Operating, Gross MarginsACET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

7

2. Health

2.1 Basic Checks

ACET has more shares outstanding than it did 1 year ago.
ACET has more shares outstanding than it did 5 years ago.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACET Yearly Shares OutstandingACET Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ACET Yearly Total Debt VS Total AssetsACET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.11, we must say that ACET is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.11, ACET is in line with its industry, outperforming 43.50% of the companies in the same industry.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.11
ROIC/WACCN/A
WACCN/A
ACET Yearly LT Debt VS Equity VS FCFACET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.34 indicates that ACET has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.34, ACET belongs to the best of the industry, outperforming 80.60% of the companies in the same industry.
ACET has a Quick Ratio of 9.34. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.34, ACET belongs to the best of the industry, outperforming 80.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.34
Quick Ratio 9.34
ACET Yearly Current Assets VS Current LiabilitesACET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1

3. Growth

3.1 Past

ACET shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.32%, which is quite impressive.
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACET will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.59%
EPS Next 2Y16.08%
EPS Next 3Y10.06%
EPS Next 5Y15.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACET Yearly Revenue VS EstimatesACET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2028 2029 2030 2031 2032 100M 200M 300M
ACET Yearly EPS VS EstimatesACET Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

0

4. Valuation

4.1 Price/Earnings Ratio

ACET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACET is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACET Price Earnings VS Forward Price EarningsACET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACET Per share dataACET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.08%
EPS Next 3Y10.06%

0

5. Dividend

5.1 Amount

No dividends for ACET!.
Industry RankSector Rank
Dividend Yield N/A

ADICET BIO INC

NASDAQ:ACET (11/10/2025, 8:00:00 PM)

After market: 0.6698 +0.01 (+1.96%)

0.6569

+0.02 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners47.51%
Inst Owner Change-0.53%
Ins Owners1.49%
Ins Owner Change2.08%
Market Cap54.69M
Revenue(TTM)N/A
Net Income(TTM)-117.11M
Analysts84.29
Price Target6.46 (883.41%)
Short Float %11.45%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.87%
Min EPS beat(2)8.37%
Max EPS beat(2)13.38%
EPS beat(4)4
Avg EPS beat(4)8.73%
Min EPS beat(4)2.1%
Max EPS beat(4)13.38%
EPS beat(8)6
Avg EPS beat(8)-1.64%
EPS beat(12)7
Avg EPS beat(12)-15.67%
EPS beat(16)10
Avg EPS beat(16)-0.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.56%
PT rev (3m)5.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)7.47%
EPS NY rev (3m)4.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.23%
ROE -72.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.34
Quick Ratio 9.34
Altman-Z -4.11
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)246.96%
Cap/Depr(5y)333.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.71%
EPS Next Y15.59%
EPS Next 2Y16.08%
EPS Next 3Y10.06%
EPS Next 5Y15.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.88%
OCF growth 3YN/A
OCF growth 5YN/A

ADICET BIO INC / ACET FAQ

What is the fundamental rating for ACET stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACET.


What is the valuation status of ADICET BIO INC (ACET) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADICET BIO INC (ACET). This can be considered as Overvalued.


Can you provide the profitability details for ADICET BIO INC?

ADICET BIO INC (ACET) has a profitability rating of 1 / 10.


Can you provide the financial health for ACET stock?

The financial health rating of ADICET BIO INC (ACET) is 7 / 10.